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Abstract:  Alpha-lipoic acid (LA), a naturally occurring dithiol compound, is an essential cofactor in metabolic reactions 
involved in energy utilization. LA improves glycemic control, reduces diabetic polyneuropathies, atherosclerosis, and allergic 
inflammation. The effects of LA on mast cell-mediated anaphylactic reactions, however, are unknown. LA dose-dependently 
inhibited systemic and passive cutaneous anaphylaxis-like reactions in mice induced by compound 48/80, a condensation 
product of N-methyl-p-methoxyphenethylamine and formaldehyde. Pretreatment with LA, prior to induction of the systemic 
anaphylaxis-like reaction with compound 48/80, reduced plasma histamine levels in a dose-dependent manner. In our in vitro 
study, LA decreased histamine release from rat peritoneal mast cells (RPMCs) triggered by compound 48/80. Moreover, an 
increase in calcium uptake activated by compound 48/80 was inhibited by LA. LA also significantly elevated intracellular cyclic 
adenosine-3',5' monophosphate (cAMP) levels in RPMCs. This inhibition of mediator release from RPMCs may be due to 
inhibition of calcium uptake and augmentation of intracellular cAMP levels. Based on these results, we suggest that LA may be 
a potential remedy for allergy-related diseases. 
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stored mediators (histamine, neutral proteases, acid 
hydrolyases, proteoglycans, chemotactic factors, cytokines 
such as tumor necrosis factor-α, interleukins, etc.) as well 
as the generation and release of newly generated mediators, 
including products of arachidonic acid metabolism and an 
array of cytokines (Galli & Tsai, 2010). Histamine, a major 
component of mast cell granules, exerts many effects related 
to the immediate-phase of allergic inflammation including 
vasodilation, increased vascular permeability, tissue edema, 
contraction of bronchial and intestinal smooth muscle, and 
increased mucus production (Galli et al., 2008). Compound 
48/80 is known to be a potent inducer of degranulation, 
responsible for the release of histamine and other chemical 
mediators associated with anaphylactic symptoms, and the 
activation of mast cells. Compound 48/80 also causes a rapid 
release of inflammatory substances only from connective 
tissue-type mast cells, specifically rat peritoneal mast cells 
(RPMCs) (Nishikawa & Kitani, 2008). Thus, RPMCs are 
Introduction
Mast cells are bone marrow-derived effector cells of the 
immune system, found abundantly in connective tissue, skin, 
mucosal membranes, and tissues which interface with the 
external environment. It has been thought that mast cells 
play a major role in the development of many physiological 
changes during allergic responses. Mast cell activation by 
both IgE-dependent and IgE-independent stimuli initiate 
degranulation which results in the fusion of cytoplasmic 
granule membranes with plasma membranes. This process is 
accompanied by the fast external release of granule-associated Anat Cell Biol 43:317~324, 2010 Yun Ho Choi, et al 318
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a good experimental model for the study of compound 
48/80-induced histamine release and anaphylaxis-like 
reactions. 
Alpha-lipoic acid (1,2-dithiolane-3-pentanoic acid; LA), 
a disulphide derivative of octanoic acid, is known to act as 
an efficient anti-oxidant and metal-chelating agent (Shay et 
al., 2009). LA has been used to treat many diseases including 
diabetic complications, polyneuropathies, atherosclerosis, 
diseases of joints, and acquired immune deficiency syndrome 
(Bilska & Wlodek, 2005). LA has also been considered as a 
therapeutic agent candidate for the treatment or prevention 
of pathologies associated with an imbalance of oxidoreductive 
status, such as neurodegeneration, ischemia-reperfusion, 
hepatic disorders, and asthma (Shay et al., 2009). Recent 
studies have revealed that LA effectively suppresses allergic 
inflammation in a murine model of asthma by reducing the 
level of reactive oxygen species (Cho et al., 2004). However, 
the effects of LA on mast cell-mediated allergic inflammation 
and cellular regulation remain unknown. 
In this study, we aimed to investigate the effect of LA on 
mast cell-mediated immediate-type hypersensitivity. The 
results clearly demonstrated that LA displays anti-allergic 
activity in both in vivo and in vitro models.
Materials and Methods
     
Materials 
Lipoic acid (LA; Thioctacid 600) was obtained from 
VIATRIS GmbH & CoKG (Frankfurt, Germany). Compound 
48/80, bovine serum albumin (BSA), disodium cromoglycate 
(DSCG) and HEPES were purchased from Sigma Chemical 
Co. (St. Louis, MO, USA). Percoll solution was purchased 
from Pharmacia (Uppsala, Sweden). LA and compound 48/80 
were freshly diluted in phosphate buffered saline (PBS) for all 
in vitro experiments.
Experimental animals 
Male ICR mice and Sprague Dawley rats were purchased 
from Damool Science (Daejeon, Korea). Animals were 
housed 3~5 per cage in laminar air-flow cabinets maintained 
at 22±1
oC and a relative humidity of 55±10% throughout the 
study. All experiments were performed in compliance with 
the guidelines approved by the Institutional Animal Care and 
Use Committee of the Chonbuk National University Medical 
School.
Compound 48/80-induced systemic anaphylaxis-like 
reactions in mice 
Mice (n=10/group) received an intraperitoneal injection of 
compound 48/80 (8 mg/kg body weight [BW]) as described 
previously (Choi et al., 2006). LA (10, 50, 100 mg/kg BW) 
was diluted in PBS and administered orally at 24, 12, and 1 
h prior to compound 48/80 administration. Mortality was 
monitored for 1 h after induction of anaphylactic shock. At 
the conclusion of the mortality test, blood was obtained by 
cardiac puncture.
     
Preparation of plasma and histamine determination 
The blood was centrifuged at 150×g for 10 min at 4
oC and 
histamine content was measured by radioenzymatic method 
from the plasma (Carvalho et al., 2010).
Compound 48/80-induced a passive cutaneous 
anaphylaxis (PCA)-like reaction  
After intradermal injection of 0.5 μg/20 μl of compound 
48/80 to the dorsal skin of each mouse, 2% Evans blue 
solution was intravenously injected into the lateral tail vein. 
LA was administered orally 24, 12, and 1 h before the injection 
of compound 48/80. As a control, a mast cell-stabilizing 
agent, DSCG, was given orally 24, 12, and 1 h prior to the 
injection of compound 48/80. Mice were euthanized with 
a terminal anesthesia dose 30 min after the 2% Evans blue 
injection. Tissue sections around the intradermal injection 
site were excised and weighed.  Extravasated Evans blue dye 
was extracted by incubation of biopsies in 1 ml formamide at 
55
oC for 24 h. Absorbance was measured at 620 nm using a 
spectrophotometer (Spectra MAX PLUS, Molecular Devices, 
CA, USA). Tissue Evans blue concentrations were quantified 
by interpolation on a standard curve of dye concentrations in 
the range of 0.01 to 30 μg/ml.
     
Preparation of mast cell suspensions and microscopic 
observation 
RPMCs were isolated as follows: rats were anesthetized 
with ether and injected with 10 ml of calcium-free HEPES-
Tyrode’s buffer (136 mM NaCl, 5 mM KCl, 11 mM NaHCO3, 
0.6 mM NaH2PO4, 5.4 mM HEPES, 1.0 mg/ml glucose) into 
the peritoneal cavity, and the abdomen gently massaged 
for about 90 s after which the peritoneal cavity was opened 
and the fluid aspirated using a Pasteur pipette. RPMCs were 
purified using a Percoll density gradient as described in detail 
elsewhere (Martynova et al., 2005). RPMC preparations were Anti-anaphylactic effects of lipoic acid
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at least 95% pure as assessed by toluidine blue staining and 
at least 98% of these cells were viable according to trypan 
blue exclusion. Purified mast cells (1×10
6 cells/ml) were 
resuspended in HEPES-Tyrode’s buffer (136 mM NaCl, 5 
mM KCl, 2 mM CaCl2, 11 mM NaHCO3, 0.6 mM NaH2PO4, 
2.75 mM MgCl2, 5.4 mM HEPES, 1.0 mg/ml BSA, 1.0 mg/ml 
glucose, 0.1 mg/ml heparin, pH 7.4), observed under a phase 
contrast microscope and photographed.
     
Mast cell viability assay 
To test the viability of cells, the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric 
assay was performed as described previously (Yoshimura et 
al., 2004). Briefly, RPMCs (1×10
6 cells/well) were incubated 
with various concentrations (1~4 mM) of LA at 37
oC for 
2 h. After addition of MTT (100 μg in 100 μl saline) cells 
were incubated at 37
oC for 1 h. The crystallized MTT was 
dissolved and absorbance measured at 570 nm with a 
spectrophotometer.
     
Histamine release assay 
Mast cell suspensions (2×10
5 cells in 200 μl) were 
preincubated with LA (1~4 mM) at 37
oC for 10 min and 
then incubated with compound 48/80 (0.25 μg/ml) for 10 
min. Following centrifugation at 150×g for 10 min, the 
amount of histamine in the supernatant was determined 
by the radioenzymatic method (Carvalho et al., 2010). The 
inhibition percentage of histamine release was calculated 
using the following formula:
Inhibition (%) = {1－(T－B)/(C－N)}×100
Control (C): compound 48/80 (＋), LA (－); Normal (N): 
compound 48/80 (－), LA (－);
Test (T): compound 48/80 (＋), LA (＋); Blank (B): 
compound 48/80 (－), LA (＋).
Measurement of 
45Ca uptake 
Purified mast cells were resuspended in HEPES-Tyrode’s 
buffer containing 
45Ca (1.5 mCi/ml; 1 Ci=3.7×10
10 becquerels; 
Perkin-Elmer Life Sciences, MA, USA) and incubated at 4
oC 
for 10 min. Mast cell suspensions were preincubated with 
LA (1~4 mM) at 37
oC for 10 min and then incubated with 
compound 48/80 (0.25 μg/ml) for 10 min. The reaction was 
stopped by the addition of 1 mM lanthanum chloride and 
samples were centrifuged 3 times at 150×g for 10 min at 
4
oC. Mast cells were then lysed with 10% Triton X-100 and 
vigorous shaking. Radioactivity of the solution was measured 
in a scintillation β-counter (Liquid Scintillation Analyzer, A 
Canberra Company, Australia).
     
Measurement of cyclic adenosine-3',5' 
monophosphate (cAMP) levels 
Mast cell suspensions were added to an equivalent volume 
(200 μl) of prewarmed buffer containing LA (1~4 mM) in 
Eppendorf tubes. The reaction was allowed to proceed for 
specific time intervals, terminated by centrifugation. Each 
sample was then added to 250 μl of 50 mM sodium acetate 
buffer (pH 6.2) under vigorous vortexing, followed by snap 
freezing in liquid nitrogen. Frozen samples were thawed and 
vortexed, and the debris sedimented by centrifugation 1,200×g 
at 4
oC for 10 min. The cAMP levels in the supernatants were 
determined with cAMP radioimmunoassay kits (Perkin-
Elmer Life Sciences).
     
Statistical analysis 
The results obtained are expressed as mean±standard error 
of the mean (SEM). Statistical evaluation of the results was 
performed using one-way ANOVA, followed by Duncan’s 
multiple range tests. Results with P<0.05 were considered 
statistically significant. 
Results
     
Effect of LA on compound 48/80-induced systemic 
anaphylaxis-like reactions 
To investigate the effect of LA on anaphylaxis-like 
reactions, we first used a mouse in vivo model with compound 
48/80. After intraperitoneal injection of compound 48/80 
(8 mg/kg BW) the mortality rate was examined for 1 h. As 
shown in Table 1, injection of compound 48/80 resulted in 
100% death. Oral administration of LA (10, 50, 100 mg/
kg BW) reduced compound 48/80-induced mortality in a 
dose-dependent manner. DSCG (reference drug) also dose-
dependently inhibited compound 48/80-induced mortality.
     
Effect of LA on compound 48/80-induced plasma 
histamine release 
LA was given at doses ranging from 10 to 100 mg/kg BW 
at 24, 12, and 1 h prior to injection of compound 48/80. Oral 
administration of LA reduced the plasma histamine release 
induced by compound 48/80 in a dose-dependent manner 
(Table 2). In addition, the reference drug DSCG attenuated Anat Cell Biol 43:317~324, 2010 Yun Ho Choi, et al 320
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compound 48/80-induced plasma histamine release.
Effect of LA on compound 48/80-induced PCA-like 
reactions 
It has been previously demonstrated that intradermal 
injection of compound 48/80 into the dorsal skin of mice 
provokes the increase of mast cell-dependent vascular 
permeability (Shinmei et al., 2004). As shown in Table 3, oral 
administration of LA dose-dependently reduced the vascular 
permeability changes induced by compound 48/80. Likewise, 
DSCG significantly inhibited the PCA-like reaction triggered 
by compound 48/80 at a dose of 100 mg/kg BW.
     
Effect of LA on mast cell viability 
An MTT conversion assay was used to determine the 
viability of RPMCs exposed to LA. Cell viability was almost 
100% after exposure to 4 mM LA for 2 h (Fig. 1); thus, LA 
had no cytotoxic effects on RPMCs.
     
Effect of LA on mast cell degranulation of RPMCs 
To investigate the inhibitory mechanism of LA 
on anaphylactic reactions, we examined compound 
48/80-induced mast cell activation (Fig. 2). Control RPMCs 
were generally spherical or oval in shape and contained many 
fine granules surrounding a prominent nucleus (Fig. 2A). 
Following stimulation with compound 48/80 for 10 min, 
RPMCs showed characteristics of mast cell degranulation 
Table 1. Inhibitory effect of lipoic acid (LA) on compound 48/80-induced sys-
temic anaphylaxis-like reaction in mice
Treatment 
(mg/kg BW)
Compound 48/80 
(8 mg/kg BW) Mortality (%)
None (PBS*) ＋ 100
LA   10 ＋ 100
  50 ＋   70
100 ＋   60
100 －     0
DSCG   10 ＋   80
100 ＋   60
Groups of mice (n=10/group) were orally administered with 300 μl of PBS or 
drugs {LA or disodium cromoglycate (DSCG)} at 24, 12 and 1 h before the 
injection of compound 48/80. The compound 48/80 solution was 
intraperitoneally given to the group of mice. Mortality (%) within 1 h following 
compound 48/80 injection was presented as the number of dead mice ×100/ 
total number of experimental mice. *PBS, phosphate-buffered saline.
Table 2. Inhibitory effect of lipoic acid (LA) on compound 48/80-induced 
plasma histamine release in mice
Treatment (mg/kg BW) Compound 48/80 
(8 mg/kg BW)
Histamine 
concentration 
(ng/ml)
Inhibition*  
(%)
  None (PBS
†) － 105.5 ± 14.9 －
  LA   10  － 117.3 ± 10.6 －
  50 － 114.1 ± 12.2 －
100 － 111.9 ± 06.7 －
  DSCG 100 － 109.4 ± 12.0 －
  None (PBS) ＋ 278.6 ± 35.3 －
  LA   10 ＋ 261.9 ± 22.5 16.52
  50 ＋  248.5 ± 18.1
‡ 22.37
100 ＋  224.3 ± 13.9
‡ 36.34
  DSCG 100 ＋  205.2 ± 17.7
‡ 44.60
LA or disodium cromoglycate (DSCG) was administered orally at 24, 12 and 1 
h prior to the injection of compound 48/80. The compound 48/80 solution was 
intraperitoneally given to the group of mice. Each histamine concentration 
represents the mean±S.E.M. of five independent experiments. *Inhibition (%) 
= {1－(T－B)/(C－N)} ×100. Control (C): compound 48/80 (＋), LA (－); 
Normal (N): compound 48/80 (－), LA (－); Test (T): compound 48/80 (＋), 
LA (＋); Blank (B): compound 48/80 (－), LA (＋). 
†PBS, phosphate-buffered 
saline. 
‡P<0.05, significantly different from the control value. DSCG (100 mg/
kg) was used as a typical antihistamine control drug. 
Table 3. Inhibitory effect of lipoic acid (LA) on compound 48/80-induced 
passive cutaneous anaphylaxis-like reaction in mice
Treatment (mg/kg BW)
Compound 
48/80 
(0.5 μg/site)
Amount of Evans 
blue (μg/g) Inhibition*(%)
None (PBS
†) － 52.43±6.70 －
LA   10 － 55.91±3.86 －
  50 － 53.14±4.23 －
100 － 52.66±8.02 －
DSCG 100 － 56.37±5.19 －
None (PBS) ＋ 168.60±7.03 －
LA   10 ＋ 152.10±8.40 17.20
 50 ＋ 139.58±2.59
‡ 25.66
100 ＋ 131.42±3.27
‡ 32.20
DSCG 100 ＋ 106.25±4.31
‡ 57.06
LA or disodium cromoglycate (DSCG) was administered orally at 24, 12 and 1 
h before the injection of compound 48/80. Twenty microliters of compound 
48/80 (0.5 μg/site) were intradermally injected to the backs of mice. Each 
amount of Evans blue represents the mean±S.E.M. of five independent 
experiments. *Inhibition (%) = {1－(T－B)/(C－N)} ×100. Control (C): 
compound 48/80 (＋), LA (－); Normal (N): compound 48/80 (－), LA (－); 
Test (T): compound 48/80 (＋), LA (＋); Blank (B): compound 48/80 (－), LA 
(＋). 
†PBS, phosphate-buffered saline. 
‡P<0.05, significantly different from the 
control value. DSCG (100 mg/kg) was used as a typical antihistamine control 
drug. Anti-anaphylactic effects of lipoic acid
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with cell swelling, cytoplasmic vacuoles, and extruded 
granules near the cell surface and in the surrounding medium 
(Fig. 2B). When RPMCs were incubated with LA alone they 
appeared similar to control cells (Fig. 2C). Pretreatment 
with LA inhibited degranulation of RPMCs induced by 
compound 48/80. The cell sizes were somewhat larger than 
the control cells (Fig. 2D); however, there was no statistical 
significant difference in size between the two groups (data not 
shown). These results suggest that LA suppresses compound 
48/80-induced mast cell degranulation.
     
Effect of LA on histamine release from RPMCs 
Histamine release from compound 48/80-treated RPMCs 
was reduced in a dose-dependent manner by LA (Fig. 3). 
DSCG also suppressed compound 48/80-induced histamine 
release. These results indicate that LA inhibits the compound 
48/80-induced anaphylactic-like reaction by blocking 
histamine release from RPMCs.
Effect of LA on calcium uptake into RPMCs 
Calcium plays an important role in the stimulus-secretion 
coupling of mast cells. It is also well established that an 
increase in calcium uptake into RPMCs contributes to 
the release of histamine (Akagi et al., 1994). Therefore, we 
measured calcium uptake and found that treatment with LA 
had no effect on calcium uptake. However, calcium uptake 
was substantially increased by stimulation of RPMCs with 
compound 48/80. This compound 48/80-elicited calcium 
uptake response was inhibited by LA in a concentration-
dependent manner (Fig. 4). At a concentration of 4 mM of 
LA, calcium uptake was nearly completely blocked. These 
results suggest that LA may inhibit mediator release by 
blocking calcium uptake into RPMCs.
     
Fig. 1. Effect of lipoic acid (LA) on rat peritoneal mast cell (RPMC) 
viability. RPMCs were treated with various concentrations of LA for 2 
h. RPMC viability was determined by MTT assay and the percentage 
of viability was calculated as a ratio of A570 of control cells (treated 
with HEPES-Tyrode’s buffer solution). Each data value represents 
the mean±standard error of the mean (SEM) of five independent 
experiments.
Fig. 2. Inverted light microscopy of RPMCs. (A) Normal RPMCs in 
HEPES-Tyrode’s buffer solution. (B) Degranulated RPMCs after the 
addition of compound 48/80. (C) RPMCs observed within 10 min 
after the addition of LA (4 mM) show similar findings as those seen in 
(A). (D) RPMCs pretreated with LA observed within 10 min after the 
addition of compound 48/80 show similar findings as those seen in (C). 
Bar=10 μm. Arrows represent RPMCs.
Fig. 3. Inhibitory effect of LA on compound 48/80-induced histamine 
release from RPMCs. RPMCs were preincubated with LA or disodium 
cromoglycate (DSCG) at 37
oC for 10 min prior to incubation 
with compound 48/80. Each bar represents the mean±SEM of five 
independent experiments.*P<0.05, significantly different from the 
control value.Anat Cell Biol 43:317~324, 2010 Yun Ho Choi, et al 322
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Effect of LA on cAMP levels of RPMCs 
Earlier findings have shown that the cAMP pathway 
participates in the modulation of mast cell activation. 
Increased cAMP is known to precede the prevention of 
mediator release from mast cells activated by compound 
48/80 or IgE (Tasaka et al., 1986). To investigate the mecha-
nism of LA involved in the reduction of mediator release 
from RPMCs stimulated by compound 48/80, we assessed 
intracellular cAMP levels. The level of cAMP was not changed 
in unstimulated RPMCs. Treatment of RPMCs with LA 
resulted in an increase in cAMP in a concentration-dependent 
manner. When RPMCs were incubated with 2 or 4 mM 
LA, the cAMP level was rapidly increased within 1 min and 
decreased to the basal level after 3 min (Fig. 5). These results 
suggest that LA may suppress mediator release by increasing 
the cAMP level in RPMCs.
Discussion
     
The present study has demonstrated that LA inhibits 
compound 48/80-induced systemic anaphylaxis-like and 
passive cutaneous anaphylaxis-like reactions in mice. 
Pretreatment with the same concentration of LA before the 
systemic anaphylaxis-like reaction also reduces the plasma 
histamine content in a dose-dependent manner. To further 
examine the mechanism by which LA attenuates mast cell-
mediated anaphylactoid reactions, we examined compound 
48/80-induced mast cell activation. Compound 48/80-induced 
histamine release from RPMCs was blocked by treatment 
with LA. Compound 48/80 is well-known to induce mast cell-
dependent, non-specific anaphylactic reactions. Additionally, 
it is widely accepted that the mechanism involved in the 
anaphylaxis-like response activated by compound 48/80 
is due to the massive release of histamine from mast cells 
and basophils (Nishikawa & Kitani, 2008). Therefore, these 
results suggest that LA could inhibit the mast cell-derived 
anaphylactoid reactions by preventing histamine release from 
RPMCs triggered by compound 48/80. 
Several reports have shown that compound 48/80 increases 
the permeability of the lipid bilayer membrane of mast cells by 
causing perturbation of the membrane (Tasaka et al., 1986). 
These findings indicate that the increase in cell membrane 
permeability may be an essential trigger for the release of 
mediators from mast cells. Thus, it is reasonable to presume 
that LA might inhibit histamine release by attenuating the 
permeability of RPMC membranes by preventing compound 
48/80-induced membrane perturbation. However, we found 
no evidence in our study to substantiate this assumption. In 
order to reveal the mechanisms involved in histamine release 
inhibition by LA, additional research is required.
To further examine the mechanisms by which LA inhibits 
mast cell-dependent anaphylaxis-like reactions, we chose 
to study two different signal transduction steps, namely 
calcium influx and cAMP production in mast cells. It is 
well-recognized that agents that elevate cAMP are effective 
Fig. 4. Inhibitory effect of LA on compound 48/80-induced calcium 
uptake in RPMCs. RPMCs were preincubated with LA at 37
oC for 10 
min prior to incubation with compound 48/80. Each bar represents 
the mean±SEM of five independent experiments. *P<0.05,  phosphate-
buffered saline (PBS) alone compared to PBS plus compound 48/80 
value; 
†P<0.05, significantly different from PBS plus compound 48/80 
value.
Fig. 5. Effect of LA on cyclic adenosine-3',5' monophosphate (cAMP) 
levels in RPMCs. RPMCs were incubated with LA for the indicated 
time periods at 37
oC. Each bar represents the mean±SEM of five 
independent experiments. *P<0.05, significantly different from samples 
treated with PBS alone.Anti-anaphylactic effects of lipoic acid
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inhibitors of mast cell and basophil activity suggesting 
that this type drug would be beneficial in the treatment of 
allergic disorders (Weston & Peachell, 1998). Moreover, it 
has been reported that a rise in cAMP levels can modulate 
secretory responses by decreasing the free cytosolic calcium 
concentrations in mast cells (White et al., 1984; Yoshii et 
al., 1988; Izushi & Tasaka, 1989). In general, stimulation of 
mast cells with compound 48/80 is believed to initiate the 
activation of a signal transduction pathway that leads to 
histamine release. Compound 48/80 initiates generation of 
superoxide anion by A-kinase inactivation by decreasing 
the intracellular cAMP concentration in RPMCs (Fukuishi 
et al., 1997). Generated superoxide anion results in inositol 
1,4,5-triphosphate (IP3) or GTP-induced calcium release 
from the endoplasmic reticulum (ER) (Akagi et al., 1994). 
Accordingly, depletion of the intracellular calcium store 
activates a calcium influx into RPMCs, which leads to an 
increase in intracellular calcium content (Hoth & Penner, 
1993). Consequently, increased intracellular calcium levels 
cause histamine release from RPMCs (Pearce et al., 1981). 
Interestingly, treatment with LA transiently increases cAMP 
levels beyond the basal level. Although the mechanism of LA-
induced cAMP production has not been elucidated, LA may 
activate adenylate cyclase directly or indirectly, to otherwise 
inhibit cAMP phosphodiesterase. In addition, LA prevents 
compound 48/80-induced calcium uptake into RPMCs in 
a dose-dependent fashion. Taken together, these results 
indicate that LA may block the generation of superoxide 
anion by A-kinase activation by increasing intracellular 
cAMP in 48/80-treated RPMCs. Hence, we speculate that 
an LA-induced decrease of superoxide anions as well as an 
increase of cAMP impedes histamine release by decreasing 
intracellular calcium content through inhibition of not only 
IP3 or GTP-induced calcium release from ER but also calcium 
uptake into compound 48/80-treated RPMCs (Yoshii et al., 
1988; Akagi et al., 1994). 
However, we cannot firmly rule out the possibility that 
cAMP is unimportant as an initiator of the secretory response 
in mast cells. Studies with RPMCs have reported that an 
increase and decrease in cAMP are not always associated 
with inhibition and mediation of secretion, respectively 
(Weston & Peachell, 1998). Moreover, extension of these 
studies to human cells has revealed that cAMP is not related 
to the initiation of the secretory process (Peachell et al., 1988; 
Weston & Peachell, 1998). Therefore, the possibility that the 
increase of cAMP by LA may not inhibit mediator release 
cannot be excluded. Although current opinion suggests that 
cAMP is not important in initiating the secretory response 
in mast cells, the cAMP signaling system affords targets for 
pharmacological intervention and any agent that augments 
cAMP in mast cells could have therapeutic possibilities in 
allergic conditions such as asthma. Thus, future studies will be 
required to elucidate the details involved in the relationship 
between cAMP levels and the secretory response by RPMCs. 
In conclusion, the results obtained in the present study 
provide evidence that LA contributes to the prevention or 
treatment of mast cell-mediated allergic diseases by inhibiting 
the release of histamine. The LA-mediated inhibition of 
mediator release from mast cells may be due to inhibition 
of calcium uptake and augmentation of intracellular cAMP 
levels. These notions along with the known anti-oxidant 
properties of LA suggest that further evaluation of its utility 
in the treatment of immediate-type allergic diseases is 
warranted.
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